ClinicalTrials.gg
Not yet recruitingNCT06368037Updated Apr 16, 2024

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

An interventional study of DragonFire Transcatheter Myocardial Radiofrequency Ablation System in Obstructive Hypertrophic Cardiomyopathy, sponsored by Hangzhou Valgen Medtech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Hangzhou Valgen Medtech Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Cardiomyopathy, Hypertrophic with a site in China — 31 open to participants now, 44 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Planned enrollment
37th of 40
10 · median 83
Started
2024
with 9 others
No phase
20 of 72
12 open now
Primary completion
2025-06
later than 14 of 43 live
Registered
41st of 72
by date
Lead sponsor
2 of 72
Hangzhou Valgen Medtech Co., Ltd

Among the 72 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 37th largest by planned enrollment of the 40 interventional ones that give a count, is one of 10 that started in 2024, is one of 20 with no phase, reaches primary completion later than 14 of the 43 other live ones, and was the 41st registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

31 of the 72 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, single-center, single-group design exploratory clinical research. No control group is set, and only subjects meeting the indications of the study device are treated. After patients sign informed consent, they are screened, and those meeting the inclusion criteria are enrolled. The treatment involves using myocardial radiofrequency ablation system and catheter-based myocardial radiofrequency ablation needle and its guidance system for treating obstructive hypertrophic cardiomyopathy. All subjects are followed up before discharge, and at 30 days, 3 months, 6 months, and 12 months postoperatively.

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Age ≥18 years; (2) Diagnosis of obstructive hypertrophic cardiomyopathy, with a peak left ventricular outflow tract gradient (LVOTG) ≥50mmHg at rest or with provocation; (3) Significant clinical symptoms including fatigue, dyspnea, exertional angina, syncope, severely affecting quality of life, and either inadequate response to standardized drug therapy or inability to tolerate drug side effects, with anatomical suitability for alcohol septal ablation and myocardial radiofrequency ablation system and use of catheter-based myocardial radiofrequency ablation needle and its guidance system; (4) functional class ≥III, or NYHA functional class II patients with one of the following: ① Severe progressive pulmonary arterial hypertension caused by outflow obstruction or resulting mitral regurgitation; ② Atrial fibrillation with associated left atrial enlargement; ③ Exercise treadmill testing indicating reduced cardiac function due to outflow obstruction; (5) Judged by the local clinical trial institution research team as high surgical risk (recommended reference criteria: advanced age or severe comorbidities, or presence of other surgical high-risk factors, such as: ≥2 moderate to severe frailty indicators or potential surgical obstacles, or ≥1 major organ dysfunction that cannot be improved after surgery, or other surgical high-risk factors judged by the cardiac team), or patients who, after being fully informed of the risks and benefits of surgery by the research team, still refuse to undergo surgery; (6) Expected survival of more than 12 months and able to adhere to the follow-up plan; (7) The subject has been informed of the nature of the study, understands the purpose of the clinical trial, voluntarily participates, and signs the form.

Exclusion criteria

Exclusion Criteria:

  • (1) Non-obstructive hypertrophic cardiomyopathy and end-stage hypertrophic cardiomyopathy; (2) Interventricular septum thickness \<15mm; (3) Significant diffuse thickening of the interventricular septum; (4) 5-year sudden cardiac death risk score (SCDI) ≥10%, or history of cardiac sudden death (SCD) events, or ventricular fibrillation, or sustained ventricular tachycardia leading to loss of consciousness, or ventricular arrhythmias causing hemodynamic instability in patients without an implanted ICD; (5) \<50%; (6) Transthoracic echocardiography suggesting the presence of intracavitary masses, thrombi, or vegetations; (7) History of surgical septal myectomy, alcohol ablation, or other interventricular septal ablation procedures; (8) Any cardiovascular intervention within 30 days or cardiac surgery within 6 months; (9) Concurrent presence of other cardiac diseases requiring surgical treatment, such as severe mitral valve disease, multi-vessel coronary artery disease, etc.; (10) Acute heart failure (defined as acute hemodynamic abnormalities occurring on the basis of primary cardiac or non-cardiac diseases, resulting in a clinical syndrome primarily characterized by acute pulmonary edema, cardiogenic shock, and elevated plasma levels of B-type natriuretic peptide) or end-stage heart failure (defined as resting heart failure, intractable pulmonary edema, or pleural or pericardial effusion despite intensified anti-heart failure treatment); (11) Preoperative presence of right bundle branch block, left bundle branch block, or atrioventricular block requiring permanent pacemaker implantation, or previously implanted permanent cardiac pacemaker; (12) Significant coronary artery disease or critical lesions requiring revascularization due to coronary perfusion-demand mismatch (QFR or FFR \<0.8), or those experiencing ischemic events within 30 days; (13) Vascular diseases affecting access for devices, such as aortic aneurysm, severe aortic stenosis, severe aortic arch or aortic valve calcification, or tortuosity or stenosis of the iliac artery; (14) Inability to determine target septal branch or balloon not being fixable in the septal branch, or cardiac anatomy unsuitable for alcohol septal ablation; (15) Hemodynamic instability, defined as systolic blood pressure \<90mmHg without the use of afterload-reducing drugs accompanied by symptoms of hypoperfusion, or cardiogenic shock; or requiring vasopressor therapy; or requiring intra-aortic balloon counterpulsation; or other hemodynamic support devices; (16) History of acute peptic ulcer or gastrointestinal bleeding within 3 months; (17) Severe (COPD) (requiring continuous home oxygen therapy or long-term use of ); (18) History of ischemic cerebrovascular accident (within the past 30 days), or severe carotid artery stenosis (ultrasound showing unilateral carotid artery stenosis >70%), or carotid artery stent implantation within 30 days, or history of hemorrhagic cerebrovascular accident (within 6 months); (19) Bleeding disorders or coagulation disorders, or to antithrombotic therapy; (20) Renal insufficiency (serum creatinine >2.0mg/dL or 177 µmol/L or \<30 mL/min/1.73m2 or undergoing dialysis treatment; (21) Active infection requiring concurrent antibiotic therapy (if temporary, patients must discontinue antibiotic use for at least 14 days before enrollment); (22) Planned pregnancy, pregnant, or lactating females; (23) Contraindications to transesophageal echocardiography or general anesthesia; (24) Expected lifespan less than 12 months, or disease that would make evaluation of treatment difficult (such as cancer, severe metabolic diseases, psychiatric disorders, etc.) unable to complete the study as required, or poor compliance as judged by the researcher; (25) Currently participating in another experimental drug or medical device clinical study with unfinished primary endpoints or clinical studies that may interfere with the endpoints of this study; (26) Other circumstances judged by the researcher as unsuitable for participation in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    The treament of DragonFire Transcatheter myocardial ablation system

    If drug therapy does not work or drug side effects are not tolerated, transaortic interventional surgery can be evaluated

    Device: DragonFire Transcatheter Myocardial Radiofrequency Ablation System

Interventions

  • DeviceDragonFire Transcatheter Myocardial Radiofrequency Ablation System

    The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography

06

What researchers measure

Primary outcomes

  1. The rate of freedom from major adverse events at 30 days postoperatively

    Definition of major adverse events: All-cause mortality within 30 days postoperatively, cardiovascular events requiring emergency intervention, malignant arrhythmias, new indication for permanent pacemaker implantation (non-reversible second-degree type II, high-degree, and third-degree atrioventricular block), left bundle branch block, right bundle branch block.

    Time frame: 30 days

  2. The success rate of treatment at 6 months postoperatively

    Definition of treatment success: Freedom from cardiac death at 6 months postoperatively, freedom from secondary re-intervention due to insufficient reduction in LVOTG, peak left ventricular outflow tract gradient (LVOTG) \<30mmHg (at rest) or ≥50% decrease compared to baseline peak LVOTG (at rest or with provocation).

    Time frame: 6 months

07

Study locations

1 site
  • Northern Theater Command General Hospital of the Chinese People's Liberation Army
    Shenyang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Jun 2025, 10 months later.

Of 52 interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2024
First posted
Apr 16, 2024
StartEst.
Aug 2024
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2026
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06368037
Lead sponsor
Hangzhou Valgen Medtech Co., Ltd
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Aug 2024 (estimated)
Primary completion
Jun 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Apr 16, 2024

Study contacts

Kangmu Ma, Phd
Contact
makangmu@valgenmed.com
+8613341773508
Yaling Han, Phd
principal investigator · Northern Theater Command General Hospital of the Chinese People's Liberation Army

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion